Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sophiris Bio Inc T.SHS


Primary Symbol: SPHS

Healthcare Biotechnology
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.


EXPM:SPHS - Post by User

Sophiris Bio Inc
Bullboard Posts
User Avatar Image
(1)
•••
Comment by rythmanon Nov 07, 2013 1:16pm
154 Views
Post# 21885536

RE:FDA approves Medivation prostate cancer drug

RE:FDA approves Medivation prostate cancer drug
The drug XTANDI has the following possible side effects:
seizure
asthonia / fatigue
back pain
diarrhea
arthralgia
hot flush
periperal edoma
musculoskeletal pain
headache
upper respiratory infections
muscular weakness
dissiness
insomnia
lower respiratory infection
spinal cord compression
cauda equing syndrome
hematuria
pareshesia
anxiety
hypertension

strangley enough they don't mention sexual dysfunction.

no wonder they want to tes PRX302!
RYTHMAN

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities